Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...

In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated ...

This webinar celebrating Global Biosimilars Week was hosted by The Center for Biosimilars® in partnership with the International Generics and Biosimilars Association. This webinar celebrating Global ...

Number 5: In 2 randomized controlled trials of maintenance therapy for inflammatory bowel disease (IBD), the subcutaneous formulation of the infliximab biosimilar CT-P13 demonstrated superiority to ...